PTEN undergoes frequent deletion and somatic mutation in endometrial cancer, glioblastoma, prostate cancer, and small-cell lung cancer.7-10 The development of CRC is closely associated with PTEN status. This evidence concerns the gene PTEN and prostate carcinoma.